ArticleProceedings of the National Academy of Sciences of the United States of America2017
Synergistic antileukemic therapies in
Abstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 62 citations in OpenAlex.
- CD40LG/CD28-Mediated Rho GTPase Signaling Drives Survival and Chemoresistance in Non-ETP T-ALL.International journal of molecular sciences · 2026Article
- Review
- Novel Therapeutic Approaches in Pediatric Acute Lymphoblastic Leukemia.International journal of molecular sciences · 2025Review
- Review
- A ROS-Responsive Dual-Targeting Drug Nanocarrier Serving as a GSI Synergist and Ferroptosis Sensitizer for T-Cell Acute Lymphoblastic Leukemia.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Chemoproteomics reveals proteome-wide covalent and non-covalent targets of withaferin A.Acta pharmacologica Sinica · 2025Article
- Therapeutic targeting of the NOTCH1 and neddylation pathways in T cell acute lymphoblastic leukemia.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Withaferin-A inhibits colorectal cancer growth and metastasis by targeting the HSP90/HIF-1α/EMT axis.Archives of medical science : AMS · 2025Article
- Loss of Notch dimerization perturbs intestinal homeostasis by a mechanism involving HDAC activity.PLoS genetics · 2024Article
- Targeting Notch signaling pathways with natural bioactive compounds: a promising approach against cancer.Frontiers in pharmacology · 2024Review
- Notch Partners in the Long Journey of T-ALL Pathogenesis.International journal of molecular sciences · 2023Review
- A Therapeutically Targetable NOTCH1-SIRT1-KAT7 Axis in T-cell Leukemia.Blood cancer discovery · 2023Article
- Withaferin A: A Dietary Supplement with Promising Potential as an Anti-Tumor Therapeutic for Cancer Treatment - Pharmacology and Mechanisms.Drug design, development and therapy · 2023Review
- Article
- RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia.Leukemia · 2022Article
- Phosphocatalytic Kinome Activity Profiling of Apoptotic and Ferroptotic Agents in Multiple Myeloma Cells.International journal of molecular sciences · 2021Article
- CARMA1 is required for Notch1-induced NF-κB activation in SIL-TAL1-negative T cell acute lymphoblastic leukemia.Journal of molecular medicine (Berlin, Germany) · 2021Article
- Biologic and Therapeutic Implications of Genomic Alterations in Acute Lymphoblastic Leukemia.Journal of clinical medicine · 2021Review
- Restoration of H3k27me3 Modification Epigenetically Silences Cry1 Expression and Sensitizes Leptin Signaling to Reduce Obesity-Related Properties.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia.Journal of hematology & oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 3 countries.
Marta Sanchez-MartinInstitute for Cancer Genetics, Columbia University, New York, NY 10032.
Alberto Ambesi-ImpiombatoInstitute for Cancer Genetics, Columbia University, New York, NY 10032.
Yue QinInstitute for Cancer Genetics, Columbia University, New York, NY 10032.
Daniel HerranzInstitute for Cancer Genetics, Columbia University, New York, NY 10032.
Mukesh BansalDepartment of Systems Biology, Columbia University, New York, NY 10032.
Tiziana GirardiKU Leuven, University of Leuven, 3000 Leuven, Belgium.
Elisabeth PaiettaMontefiore Medical Center, New York, NY 10467.
Martin S TallmanDepartment of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065.
Jacob M RoweTechnion, Israel Institute of Technology, Haifa 3200003, Israel.
Kim De KeersmaeckerKU Leuven, University of Leuven, 3000 Leuven, Belgium.ORCID 0000-0002-7420-9531
Andrea CalifanoDepartment of Systems Biology, Columbia University, New York, NY 10032.
Adolfo A FerrandoInstitute for Cancer Genetics, Columbia University, New York, NY 10032; af2196@columbia.edu.
Cancer Genetics (United States) · USColumbia University · USKU Leuven · BEMemorial Sloan Kettering Cancer Center · USMontefiore Medical Center · USTechnion – Israel Institute of Technology · IL
Funding
Project-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · 2014 to 2026
$167.6MECOG-ACRIN Biospecimen Bank to Support NCTNU24CA196172 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI STANLEY R. HAMILTON, Scott D Jewell · 2015 to 2026
$41.1MSystematic pharmacological targeting of the core mechanisms responsible for maintaining cancer cell stateU54CA209997 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA, HONIG, BARRY H · 2016 to 2021
$10.9MMontefiore Academic Community NCORP ProgramUG1CA189859 · NCI · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI Balazs Halmos, Della Makower · 2014 to 2026
$10.8MSystems Biology of Tumor Progression and Drug ResistanceU01CA168426 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA · 2012 to 2016
$6.5MSystematic Identification and Pharmacological Targeting of Tumor Dependencies for Precision Cancer MedicineU01CA217858 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA · 2017 to 2021
$6.1MECOG Clinical TrialsU10CA017145 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI BENSON, AL B · 1985 to 2013
$6.1MMolecular pathways and targeted therapies in human leukemiaR35CA210065 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI FERRANDO, ADOLFO A. · 2017 to 2021
$4.7MNetwork Lead Academic Participating Site: Memorial Sloan-Kettering Cancer CenterU10CA180791 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI AGHAJANIAN, CAROL, MORRIS, MICHAEL J · 2014 to 2018
$4.6MECOG-ACRIN INTEGRATED LEUKEMIA TRANSLATIONAL RESEARCH CENTERU10CA180827 · NCI · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI LEVINE, ROSS L, MELNICK, ARI M. · 2014 to 2018
$3.0MONCOLOGYU10CA014958 · NCI · YESHIVA UNIVERSITY · PI SPARANO, JOSEPH A. · 1985 to 2013
$2.2MMechanisms of T-Cell Leukemogenesis Induced by Notch1R01CA120196 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI FERRANDO, ADOLFO A. · 2007 to 2011
$2.1MEuropean Research Council 334946NCI NIH HHS K99 CA197869NCI NIH HHS R00 CA197869NCI NIH HHS R01 CA120196NCI NIH HHS R01 CA129382NCI NIH HHS R35 CA210065NCI NIH HHS U01 CA168426NCI NIH HHS U01 CA217858NCI NIH HHS U10 CA014958NCI NIH HHS U10 CA017145NCI NIH HHS U10 CA180791NCI NIH HHS U10 CA180820NCI NIH HHS U10 CA180827NCI NIH HHS U24 CA196172NCI NIH HHS U54 CA209997NCI NIH HHS UG1 CA189859NIH HHS S10 OD012351NIH HHS S10 OD021764
Abstract
The
Indexed as
Amyloid Precursor Protein SecretasesAnimalsAntineoplastic Combined Chemotherapy ProtocolsCell Line, TumorDrug Resistance, NeoplasmDrug SynergismeIF-2 KinaseEnzyme InhibitorsGene Expression ProfilingHumansMiceMice, Inbred C57BLMice, KnockoutMolecular Targeted TherapyPhosphorylationPrecursor T-Cell Lymphoblastic Leukemia-LymphomaAmyloid Precursor Protein SecretaseseIF-2 KinaseEnzyme InhibitorsNOTCH1 protein, humanReceptor, Notch1withaferin AWithanolidesleukemiaNOTCH1protein translationsynergyT-ALL
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.